Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07461831 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

CD19/ CD22 Bispecific CAR-T Cell Therapy for Relapsed/ Refractory Large B-cell Lymphoma

StatusCompleted
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial completed Show 4 more changesShow less
    • Final enrollment: 74 participants (planned 100)
    • Study completion date changed from estimate of Dec 31, 2027 to Sep 29, 2026
    • Interventions: CD19/CD22 bispecific CAR-T cells (Drug) to CD19/CD22 bispecific CAR-T cells (Drug)
    • Eligibility criteria expanded, about 20 words
  2. Trial status changed: Recruiting → Active, Not Recruiting
    • Primary completion moved earlier from Dec 31, 2026 to Apr 18, 2026
    • Site details revised
    v3
  3. Secondary endpoints revised (4)
    • Study description expanded, about 1 word
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
CAR-T cell therapy targeting CD19 has been shown to be effective in heavily-pretreated B-cell ALL or NHL, but relapses post-CAR-T are common, and CD19 antigen loss is one of the reasons. Thus, the investigators supposed that CD19/CD22 bispecific CAR-T cell therapy would be more effective and less relapses would occur in B- NHL. In this prospective phase 2 clinical trial, the investigators aim to explore the efficacy and safety of CD19/CD22 bispecific CAR-T cell therapy in relapsed/refractory Large B cell lymphoma.
Trial Details
NCT Number NCT07461831
Lead Sponsor Beijing Tongren Hospital
Conditions
(from sponsor)		 Large B-Cell Lymphoma (LBCL)
Enrollment 74 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov